Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of$1.17 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this drug developer would post a loss of $0.87 per share when it actually produced a loss of$0.90, delivering a surprise of -3.45%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Travere, which belongs to the ...